novo nordisk tirzepatide has filed a lawsuit against Eli Lilly, alleging that the company's advertising for its blockbuster GLP-1 obesity and diabetes drugs misleads consumers by using outdated clinical trial comparisons. The Danish Novo Nordisk and Eli Lilly:

The Aqua Skin Veniscy 22 injection is then applied, protecting the skin with a thin coating of plastic while providing outstanding results

This strikes me as a big deal and perhaps a high price to pay for losing an average of 8 extra pounds (at least short term.) These adverse events are also important when we consider these drugs for secondary uses

On this basis, we estimate that 4,590 ASCs (4,271 + 319) will submit data for the ASCQR Program for the CY 2026 reporting period and subsequent years unless otherwise noted

Novo Nordisk maintains first-to-market advantage with semaglutide across diabetes (Ozempic), obesity (Wegovy), and oral (Rybelsus) formulations, with the oral version launching in January 2026 following December 2025 FDA approval [3]

WegovyTM Clinical Trial 1 Results | WegovyTM (Semaglutide) Injection 2.4 mg

3 * Based on the efficacy estimand: estimated efficacy in an idealized scenario in which all patients stayed on treatment and without initiation of additional glucose-lowering medication